Along this line, patients with bladder cancer treated with aspirin, an inhibitor of cyclooxygenase (COX) 1 and 2 (encoded by PTGS1 and PTGS2, respectively), while undergoing intravesical immunotherapy benefited from better response rates (Lipsky et al., 2013). This evidence concerns the gene PTGS1 and urinary bladder cancer.